# A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China

> **NCT05268068** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 30 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Risankizumab
- **DRUG:** Risankizumab

## Key facts

- **NCT ID:** NCT05268068
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-27
- **Primary completion:** 2020-04-26
- **Final completion:** 2020-04-26
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05268068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05268068, "A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05268068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*